We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.19B
AUM Growth
+$35.3M
Cap. Flow
+$22.8M
Cap. Flow %
0.54%
Top 10 Hldgs %
34.58%
Holding
124
New
4
Increased
47
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$19.7M
2
RVMD icon
Revolution Medicines
RVMD
+$17.3M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.3M
4
PLRX icon
Pliant Therapeutics
PLRX
+$14M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.7M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$58.6M
2
PEN icon
Penumbra
PEN
+$19.1M
3
IMCR icon
Immunocore
IMCR
+$18M
4
ALGN icon
Align Technology
ALGN
+$16.2M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.08%
2 Consumer Staples 1.05%
3 Industrials 0.87%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
51
BioMarin Pharmaceuticals
BMRN
$13.3B
$25.7M 0.61%
264,500
– –
SWAV
52
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$25M 0.6%
115,100
– –
LEGN icon
53
Legend Biotech
LEGN
$4B
$22.1M 0.53%
458,265
+7,799
+2% +$381K
LFST icon
54
Lifestance Health
LFST
$4.55B
$21.5M 0.51%
2,900,000
+200,000
+7% +$1.11M
CNMD icon
55
CONMED
CNMD
$1.48B
$21.3M 0.51%
205,000
– –
BCRX icon
56
BioCryst Pharmaceuticals
BCRX
$2.51B
$19.5M 0.46%
2,334,085
+443,348
+23% +$4.27M
AMYT
57
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$19.3M 0.46%
1,325,625
– –
AZTA icon
58
Azenta
AZTA
$1.54B
$19.2M 0.46%
431,200
+79,700
+23% +$3.95M
INZY
59
DELISTED
Inozyme Pharma
INZY
$18.4M 0.44%
3,214,900
+128,873
+4% +$341K
MLYS icon
60
Mineralys Therapeutics
MLYS
$2.41B
$18.3M 0.44%
+1,167,492
New +$19.7M
CMPX icon
61
Compass Therapeutics
CMPX
$400M
$18M 0.43%
5,513,788
+180,600
+3% +$709K
DVAX
62
DELISTED
Dynavax Technologies
DVAX
$17.8M 0.42%
1,813,758
– –
IMTX icon
63
Immatics
IMTX
$1.33B
$17.3M 0.41%
2,513,923
+239,139
+11% +$1.96M
MRSN
64
DELISTED
Mersana Therapeutics
MRSN
$16.9M 0.4%
164,152
– –
CYTK icon
65
Cytokinetics
CYTK
$10.8B
$15.8M 0.38%
447,600
+4,600
+1% +$188K
COLL icon
66
Collegium Pharmaceutical
COLL
$882M
$15.6M 0.37%
650,000
-75,000
-10% -$1.99M
RVMD icon
67
Revolution Medicines
RVMD
$44.4B
$15.2M 0.36%
+702,712
New +$17.3M
CLDX icon
68
Celldex Therapeutics
CLDX
$3.37B
$15.2M 0.36%
421,504
– –
WRBY icon
69
Warby Parker
WRBY
$3.26B
$13.8M 0.33%
1,300,000
+81,025
+7% +$1.11M
PLRX icon
70
Pliant Therapeutics
PLRX
$64.4M
$13.1M 0.31%
+491,221
New +$14M
ANAB icon
71
AnaptysBio
ANAB
$1.64B
$12.5M 0.3%
576,600
– –
FOLD
72
DELISTED
Amicus Therapeutics
FOLD
$11.8M 0.28%
1,063,806
– –
KDNY
73
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.7M 0.28%
507,512
– –
FOCL
74
EDAP TMS S.A.
FOCL
$228M
$11.4M 0.27%
1,030,000
+120,000
+13% +$1.36M
RLAY icon
75
Relay Therapeutics
RLAY
$4.37B
$11.1M 0.26%
673,966
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Rock Springs Capital Management held 124 positions worth $4.19B, up 0.85% from $4.16B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management's Q1 2023 filing shows 4 new, 47 increased, 8 reduced and 3 closed positions. Its largest new stake was Mineralys Therapeutics: 1,167,492 shares worth $18.3M. The largest sale was Baxter International, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2023 buy was Mineralys Therapeutics: 1,167,492 shares worth $18.3M.
  • Rock Springs Capital Management added most to Karuna Therapeutics, Inc. Common Stock in Q1 2023, an estimated $15.3M increase.
  • Rock Springs Capital Management's biggest Q1 2023 reduction was Penumbra, cutting an estimated $19.1M.
  • Rock Springs Capital Management fully exited Baxter International in Q1 2023, selling an estimated $58.6M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $4.19B portfolio in Q1 2023.
  • Rock Springs Capital Management opened 4 new positions and closed 3 in Q1 2023.
  • Rock Springs Capital Management's portfolio value rose 0.85% quarter-over-quarter to $4.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2023, filed 15 May 2023.